Antiviral Drugs - Southern Asia

  • Southern Asia
  • The revenue of the Antiviral Drugs market in Southern Asia is expected to reach US$0.53bn in 2024.
  • Furthermore, it is projected that the market will exhibit an annual growth rate of 0.47% between 2024 and 2028, leading to a market volume of US$0.54bn by 2028.
  • In terms of global comparison, United States is anticipated to generate the highest revenue, amounting to US$32,110.00m in 2024.
  • The demand for antiviral drugs in Southern Asia has surged due to the high prevalence of viral diseases in the region.

Key regions: France, Brazil, South Korea, India, China

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Antiviral Drugs market in Southern Asia has been steadily developing in recent years, driven by a combination of customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors.

Customer preferences:
Customers in Southern Asia have shown a growing demand for antiviral drugs due to the increasing prevalence of viral diseases in the region. With a large population and high population density, the spread of viral diseases is a major concern in Southern Asia. Additionally, customers in the region tend to prefer affordable and easily accessible healthcare options, which has led to the growth of generic antiviral drugs in the market.

Trends in the market:
One of the major trends in the Antiviral Drugs market in Southern Asia is the increasing focus on research and development of new drugs to combat emerging viral diseases. With the outbreak of diseases such as COVID-19, there has been a renewed emphasis on developing effective antiviral drugs. Another trend in the market is the growing popularity of combination therapy, which involves using multiple antiviral drugs to increase effectiveness and reduce the risk of drug resistance.

Local special circumstances:
Southern Asia has a unique set of circumstances that have contributed to the growth of the Antiviral Drugs market. For example, the region has a high burden of viral diseases such as dengue fever, hepatitis B and C, and HIV/AIDS. Additionally, the region has a large population of low-income individuals who may not have access to expensive branded drugs, which has led to the growth of generic antiviral drugs in the market.

Underlying macroeconomic factors:
The Antiviral Drugs market in Southern Asia is also influenced by underlying macroeconomic factors such as government policies and healthcare infrastructure. Many governments in the region have implemented policies to promote the use of generic drugs, which has led to the growth of the generic antiviral drugs market. Additionally, the region has seen significant improvements in healthcare infrastructure in recent years, which has made antiviral drugs more accessible to the population.In conclusion, the Antiviral Drugs market in Southern Asia is developing due to a combination of customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. The increasing prevalence of viral diseases in the region, the focus on research and development of new drugs, and the growing popularity of combination therapy are all contributing to the growth of the market. Additionally, government policies and improvements in healthcare infrastructure are making antiviral drugs more accessible to the population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)